Global Resistance of Neisseria gonorrhoeae

When Theory Becomes Reality

David A. Lewis


Curr Opin Infect Dis. 2014;27(1):62-67. 

In This Article

Gonococcal Resistance to Fluoroquinolones

The introduction of fluoroquinolones in the early 1980s was initially greeted with the same enthusiasm as penicillin in the 1940s. Although not suitable for pregnant women, fluoroquinolones such as ciprofloxacin showed great promise as a single-dose treatment against N. gonorrhoeae with little or no side-effects. However, treatment failures to both the low dose (250 mg) and higher dose (500 mg) regimens were reported in the early 1990s as a result of mutations in the quinolone resistance determining regions of the gyrA and parC genes.[3] Like resistance to penicillin and tetracycline, fluoroquinolone resistance spread rapidly across the world, initially within the Asia-Pacific region in the 1990s, in Europe and North America at the turn of the century, and most recently in Africa and South America.[3]